resveratrolnootropicscognitive performancemitochondriapolyphenolrandomized controlled trialbrain agingbioavailabilityantioxidant

Resveratrol and Cognition: What the Trial Evidence Actually Shows

Three human trials link resveratrol to measurable memory or cerebrovascular gains in older and postmenopausal adults, but the two largest pooled analyses of the same literature found no significant cognitive benefit. Here is what the primary research shows, and why bioavailability may explain the gap.

11 November 20269 min read

Research context: This article discusses peer-reviewed randomized controlled trials and systematic reviews. It is intended for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making changes to diet, lifestyle, or supplementation.

A compound with more marketing momentum than its trial record supports

Resveratrol built its reputation on red wine headlines and rodent longevity studies, and that reputation has outrun what the human cognitive trials actually show. The honest picture, once the individual trials are read against the pooled analyses that followed them, is a genuine split: three separate randomized trials from credible academic groups report measurable benefits to memory, verbal recall, or cerebrovascular function, while the two systematic reviews that pooled the available trial data found no significant effect on cognition at all. Both halves of that record are real. Neither should be read in isolation.

What resveratrol is supposed to do

Resveratrol is a stilbene polyphenol found in the skin of red grapes, in red wine, in peanuts, and in the roots of Polygonum cuspidatum, the plant used in most commercial extracts. Its proposed route to brain benefit runs through sirtuin 1 (SIRT1) activation and AMP-activated protein kinase (AMPK) signaling, the same mitochondrial biogenesis pathway that NAD+ precursors are proposed to support, a mechanistic overlap discussed in our NAD+ and NMN for brain health review. Resveratrol also has direct antioxidant and vasodilatory activity via nitric oxide signaling in cerebral vasculature, which is the basis for the cerebrovascular outcomes several of the human trials below actually measured. Readers interested in the broader bioenergetic framing behind these mitochondrial mechanisms can see our mitochondria and cognitive performance overview for the underlying model.

None of this is unique to resveratrol; it is the standard pitch for most polyphenol nootropics. What distinguishes resveratrol's evidence base is that it has actually been tested in several well-designed human cognitive trials, which makes it a useful case study in how a real but modest signal in individual trials can disappear once it is pooled.

The positive signal: three human trials

Witte et al., 2014 (Journal of Neuroscience). Forty-six healthy, overweight older adults (50 to 75 years) took 200 mg/day of resveratrol or placebo for 26 weeks in a double-blind, placebo-controlled design. The resveratrol group showed significantly better retention of words over 30 minutes compared to placebo (p = 0.038), along with significant increases in hippocampal functional connectivity, decreases in glycated hemoglobin (HbA1c), and decreases in body fat relative to placebo (all p < 0.05). Increases in functional connectivity between the left posterior hippocampus and the medial prefrontal cortex correlated with the memory gains and with the HbA1c reductions (Witte AV, Kerti L, Margulies DS, Flöel A, "Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults," Journal of Neuroscience 2014;34(23):7862-7870, PMID: 24899709). The authors describe this as initial evidence, not an established effect, and the sample size is small.

Evans, Howe, and Wong, 2017 (Nutrients). Eighty postmenopausal women (45 to 85 years) took trans-resveratrol or placebo for 14 weeks in a randomized, placebo-controlled trial run at the University of Newcastle in Australia. Resveratrol produced 17 percent increases in cerebrovascular responsiveness to both hypercapnia (p = 0.010) and cognitive stimulation (p = 0.002) relative to placebo, along with significant improvements in verbal memory (p = 0.041) and overall cognitive performance (p = 0.020). The cognitive gains correlated with the cerebrovascular responsiveness increase (r = 0.327, p = 0.048) (Evans HM, Howe PR, Wong RH, "Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial," Nutrients 2017;9(1):27, PMID: 28054939).

Thaung Zaw, Howe, and Wong, 2021 (Clinical Nutrition). The same Newcastle group followed up with a considerably larger and longer trial: 125 postmenopausal women in a 24-month randomized, double-blind, placebo-controlled crossover design, taking 75 mg of trans-resveratrol twice daily (150 mg/day total) for 12 months before crossing over to the alternate treatment for another 12 months. Resveratrol produced a statistically significant improvement in the trial's primary outcome, overall cognitive performance, relative to placebo (Cohen's d = 0.170, p = 0.005). Women 65 and older showed a relatively larger verbal memory benefit than younger participants. Secondary cerebrovascular and metabolic outcomes also improved, including resting cerebral blood flow velocity (d = 0.275, p = 0.001), cerebrovascular responsiveness to hypercapnia (d = 0.307, p = 0.027), fasting insulin (d = 0.174, p = 0.025), and an insulin resistance index (d = 0.102, p = 0.034) (Thaung Zaw JJ, Howe PR, Wong RH, "Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study," Clinical Nutrition 2021;40(3):820-829, PMID: 32900519). This is the largest and longest resveratrol-cognition trial published to date, and it is the strongest single piece of positive evidence in the record.

The pooled picture: two meta-analyses say no

Farzaei et al., 2017/2018 (Pharmacological Research). This systematic review and meta-analysis pooled four randomized clinical trials covering 226 individuals and searched for effects on memory, cognitive performance, and mood. The authors concluded that resveratrol had no significant effect on memory and cognitive performance as assessed by auditory verbal learning tests, including learning ability, delayed recall, retention, and recognition, with effect sizes described as non-significant and effectively at zero. The one positive finding was on mood: two subscales of the Profile of Mood States, vigor and fatigue, improved significantly with resveratrol, while tension, depression, anger, and confusion did not (Farzaei MH, Rahimi R, Nikfar S, Abdollahi M, "Effect of resveratrol on cognitive and memory performance and mood: A meta-analysis of 225 patients," Pharmacological Research 2018;128:338-344, PMID: 28844841).

Wu et al., 2025 (Frontiers in Pharmacology). The most recent and largest pooled analysis specifically targeted postmenopausal women, the same population the Newcastle trials studied, combining ten randomized controlled trials covering 928 participants with intervention durations from 14 weeks to 24 months. Across every cognitive domain tested, including processing speed, language, episodic memory, verbal memory (Rey Auditory Verbal Learning Test, immediate and delayed), working memory, and cognitive flexibility, the pooled weighted mean differences were not statistically significant, with confidence intervals crossing zero in each case. Resveratrol did produce significant reductions in composite pain scores and in a bone-resorption marker (CTX), but no measurable cognitive, mood, metabolic, or cardiovascular benefit emerged once the trials were combined (Wu W, Meng T, Jin F, Li J, Huang J, Guo Z, Yu M, Zhou Y, "Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis," Frontiers in Pharmacology 2025;16:1588284, DOI: 10.3389/fphar.2025.1588284).

Notably, the 2021 Thaung Zaw trial, the single strongest positive result, is among the ten trials pooled into the 2025 null result. A large effect in one well-conducted trial can still wash out once it is averaged against smaller or shorter trials with flatter results, which is exactly what a meta-analysis is designed to reveal.

Why the trials disagree: bioavailability and population

Part of the explanation is pharmacokinetic. Resveratrol is absorbed well from the gut, at least 70 percent of an oral dose in one tracer study, but it is almost immediately sulfated and glucuronidated by the intestine and liver, so only trace amounts of unmetabolized resveratrol ever reach the bloodstream intact. Peak plasma concentrations of the parent compound were below 5 ng/mL in that study even after a direct intravenous comparison confirmed good absorption, with a plasma half-life of roughly 9 hours (Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK, "High absorption but very low bioavailability of oral resveratrol in humans," Drug Metabolism and Disposition 2004;32(12):1377-1382, PMID: 15333514). Whether resveratrol's metabolites retain meaningful biological activity in the brain, or whether the parent compound needs to cross the blood-brain barrier intact to produce the effects seen in the positive trials, is not settled, and this uncertainty sits underneath every dosing decision made in the trials above.

Population and duration differences compound the problem. The positive postmenopausal trials studied a group with age- and estrogen-related endothelial decline, where a vasodilatory compound has a specific deficit to correct, and the strongest result came from the longest intervention (24 months). The null meta-analyses pool trials of widely varying duration and, in Farzaei's case, a small and heterogeneous sample. Reading the record honestly: resveratrol has a biologically plausible, modest, duration-dependent effect on cerebrovascular function and memory in postmenopausal women specifically, and the generalized claim that resveratrol improves cognition in adults broadly is not supported once the available trials are pooled together.

Key takeaways

Three individual randomized trials, including the largest and longest resveratrol-cognition trial published to date, found statistically significant improvements in memory or cerebrovascular function with 150 to 200 mg/day of resveratrol taken for 14 weeks to 24 months, concentrated in postmenopausal women. Two independent meta-analyses pooling the same class of trials, one covering 226 participants and one covering 928 participants, found no significant cognitive benefit across any domain tested, despite the larger and more recent analysis including the strongest positive trial in its pooled sample. Resveratrol's very low oral bioavailability, driven by rapid intestinal and hepatic conjugation, is a plausible mechanistic reason the signal is inconsistent across trials and may not generalize beyond the population and duration where it has actually been demonstrated.

FAQ

Does resveratrol improve memory?

The honest answer is population- and duration-dependent. In postmenopausal women taking 150 mg/day for 24 months, the largest trial to date found a statistically significant improvement in overall cognitive performance and a larger verbal memory benefit in women 65 and older. In pooled analyses spanning shorter trials and broader eligibility criteria, no significant cognitive benefit emerges. There is no trial evidence that resveratrol improves memory in younger, healthy adults.

Why do the individual trials and the meta-analyses disagree?

Meta-analyses pool effect sizes across trials of different duration, dose, and population, which can dilute a real but modest effect seen in one well-designed trial, particularly when that trial is the longest and uses the most sensitive population. The 2025 meta-analysis that found no cognitive benefit in postmenopausal women included the 2021 trial that found the field's strongest positive result, and still returned a null pooled estimate. Low and variable oral bioavailability of resveratrol likely also contributes to inconsistent results across trials that use different formulations or co-administer compounds like piperine that affect absorption.

Is resveratrol related to the NAD+ and mitochondrial cognition research on this site?

Mechanistically, yes. Resveratrol is proposed to act partly through SIRT1 and AMPK, the same mitochondrial biogenesis pathway implicated in NAD+ precursor research, though the human trial evidence for each compound stands on its own and should not be conflated. See our NAD+ and NMN for brain health review for that adjacent literature.